tucatinib (Tukysa) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Breakthrough Therapy FDA Priority Review FDA
AACT DrugBank PubChem

Active Ingredient History

NOW
  • Now
Tucatinib, sold under the brand name Tukysa, is an anticancer medication used for the treatment of HER2-positive breast cancer. It is a small molecule inhibitor of HER2. It was developed by Array BioPharma and licensed to Cascadian Therapeutics.   Wikipedia

Chemistry

  • SMILES: Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc5ccn6ncnc6c5
  • InChIKey: SDEAXTCZPQIFQM-UHFFFAOYSA-N
  • Mol. Mass: 480.53
  • ALogP: 5.09
  • ChEMBL Molecule:
    tucatinib  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$57.7530 - $148.7438
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

tucatinib

Organizations (41)

Research & Development (41)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (19)

Approved Indications (2)


 

Breast Neoplasms

Colorectal Neoplasms (approved 2023)

Experimental Indications - Clinical Trial Phases 1-4 (19)


 

Adenocarcinoma (Phase 1)

Biliary Tract Neoplasms (Phase 2)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Central Nervous System Diseases (Phase 1/Phase 2)

Cholangiocarcinoma (Phase 1)

Colorectal Neoplasms (Phase 2)

Drug Interactions (Phase 1)

Esophageal Neoplasms (Phase 2/Phase 3)

Gallbladder Neoplasms (Phase 1)

Healthy Volunteers (Phase 1)

Liver Diseases (Phase 1)

Meninges (Phase 2)

Neoplasms (Phase 2)

Stomach Neoplasms (Phase 2/Phase 3)

Urologic Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Uterine Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 40
  • # of Trial Organizations: 41

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue